Penetratin improves tumor retention of single-chain antibodies: A novel step toward optimization of radioimmunotherapy of solid tumors

Maneesh Jain, Subhash C. Chauhan, Ajay P. Singh, Ganesh Venkatraman, David Colcher, Surinder Kumar Batra

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-associated glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 hours postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, respectively, of that accumulated at 8 hours postinjection. The tumor-to-blood ratios at 24 hours postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, respectively, whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiography of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of sc(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.

Original languageEnglish (US)
Pages (from-to)7840-7846
Number of pages7
JournalCancer Research
Volume65
Issue number17
DOIs
StatePublished - Sep 1 2005

Fingerprint

Radioimmunotherapy
Single-Chain Antibodies
Trans-Activators
Neoplasms
Pharmacokinetics
Immunoglobulin G
Monoclonal Antibodies
penetratin
Cell-Penetrating Peptides
Whole Body Imaging
Radiopharmaceuticals
Autoradiography
Half-Life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Penetratin improves tumor retention of single-chain antibodies : A novel step toward optimization of radioimmunotherapy of solid tumors. / Jain, Maneesh; Chauhan, Subhash C.; Singh, Ajay P.; Venkatraman, Ganesh; Colcher, David; Batra, Surinder Kumar.

In: Cancer Research, Vol. 65, No. 17, 01.09.2005, p. 7840-7846.

Research output: Contribution to journalArticle

Jain, Maneesh ; Chauhan, Subhash C. ; Singh, Ajay P. ; Venkatraman, Ganesh ; Colcher, David ; Batra, Surinder Kumar. / Penetratin improves tumor retention of single-chain antibodies : A novel step toward optimization of radioimmunotherapy of solid tumors. In: Cancer Research. 2005 ; Vol. 65, No. 17. pp. 7840-7846.
@article{0fcb1851101b46b1bccf310c3a538a1a,
title = "Penetratin improves tumor retention of single-chain antibodies: A novel step toward optimization of radioimmunotherapy of solid tumors",
abstract = "Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-associated glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 hours postadministration with a control (no peptide), penetratin, and TAT were 27.25{\%}, 79.84{\%}, and 48.55{\%}, respectively, of that accumulated at 8 hours postinjection. The tumor-to-blood ratios at 24 hours postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, respectively, whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiography of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of sc(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.",
author = "Maneesh Jain and Chauhan, {Subhash C.} and Singh, {Ajay P.} and Ganesh Venkatraman and David Colcher and Batra, {Surinder Kumar}",
year = "2005",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-05-0662",
language = "English (US)",
volume = "65",
pages = "7840--7846",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Penetratin improves tumor retention of single-chain antibodies

T2 - A novel step toward optimization of radioimmunotherapy of solid tumors

AU - Jain, Maneesh

AU - Chauhan, Subhash C.

AU - Singh, Ajay P.

AU - Venkatraman, Ganesh

AU - Colcher, David

AU - Batra, Surinder Kumar

PY - 2005/9/1

Y1 - 2005/9/1

N2 - Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-associated glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 hours postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, respectively, of that accumulated at 8 hours postinjection. The tumor-to-blood ratios at 24 hours postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, respectively, whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiography of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of sc(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.

AB - Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-associated glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 hours postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, respectively, of that accumulated at 8 hours postinjection. The tumor-to-blood ratios at 24 hours postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, respectively, whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiography of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of sc(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.

UR - http://www.scopus.com/inward/record.url?scp=24744450185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24744450185&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-0662

DO - 10.1158/0008-5472.CAN-05-0662

M3 - Article

C2 - 16140953

AN - SCOPUS:24744450185

VL - 65

SP - 7840

EP - 7846

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -